Anavex Life Sciences (AVXL) Capital Expenditures (2013 - 2014)
Anavex Life Sciences recorded quarterly Capital Expenditures of $688.0 in Q3 2014, down 70.43% quarter-over-quarter from $2327.0 in Q4 2013.
Anavex Life Sciences' Capital Expenditures history runs 2 years deep, the most recent figure standing at $688.0 for Q3 2014.
- In Q3 2014, Capital Expenditures changed N/A year-over-year to $688.0; the TTM figure through Jun 2015 stood at $688.0 (down 70.43% YoY), while the FY2014 annual figure was $3015.0, changed N/A from the prior year.
- Capital Expenditures came in at $688.0 for Q3 2014 at Anavex Life Sciences, down from $2327.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $2327.0 in Q4 2013 to a low of $688.0 in Q3 2014.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | 688.00 |
| Sep 30, 2014 | 688.00 |
| Dec 31, 2013 | 2,327.00 |
| Dec 31, 2013 | 2,327.00 |